Reata Pharmaceuticals Inc. (RETA)

75.74
NASDAQ : Health Technology
Prev Close 72.99
Day Low/High 73.55 / 77.80
52 Wk Low/High 47.50 / 104.53
Avg Volume 220.00K
Exchange NASDAQ
Shares Outstanding 24.48M
Market Cap 2.20B
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXL, BIG, DK, FOSL, NFG, NKTR, SRC, TGH, UTSI Downgrades: AIRG, AXAS, HPP, PAA, QDEL, RAD Initiations: FND, RETA, TOCA Read on to get TheStreet Quant Ratings' detailed report:

2 Key 'Rules' When Investing in Biotech Stocks

2 Key 'Rules' When Investing in Biotech Stocks

Remembering these 'rules of the road' is vital in this highly volatile space.

Biotech Stocks Getting Their Due Respect

Biotech Stocks Getting Their Due Respect

Here are two I think will bounce back before the end of the year.

Reata Pharmaceuticals Reaches Analyst Target Price

Reata Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Reata Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $55.33, changing hands for $76.55/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

How I Invest In Biotech Stocks

How I Invest In Biotech Stocks

Here's two 'rules of the road' when investing in this highly volatile space.

3 Good Bargain Stocks With Insider Buying

3 Good Bargain Stocks With Insider Buying

I continue to keep a 'shopping list' at the ready for the next dip in the market.

Reata Pharmaceuticals is Now Oversold (RETA)

Reata Pharmaceuticals is Now Oversold (RETA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

The January Effect Is on Time This Year

The January Effect Is on Time This Year

I continue to believe that biotech and biopharma stocks will outperform in 2018.

Reata Pharmaceuticals is Now Oversold (RETA)

Reata Pharmaceuticals is Now Oversold (RETA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Reata Pharmaceuticals At $20, Earn 17.6% Annualized Using Options

Commit To Buy Reata Pharmaceuticals At $20, Earn 17.6% Annualized Using Options

Investors considering a purchase of Reata Pharmaceuticals Inc shares, but cautious about paying the going market price of $26.60/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $20 strike, which has a bid at the time of this writing of $1.65.

Reata Pharmaceuticals Becomes Oversold (RETA)

Reata Pharmaceuticals Becomes Oversold (RETA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Reata Pharmaceuticals At $25, Earn 20% Using Options

Commit To Buy Reata Pharmaceuticals At $25, Earn 20% Using Options

Investors eyeing a purchase of Reata Pharmaceuticals Inc stock, but tentative about paying the going market price of $28.24/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $25 strike, which has a bid at the time of this writing of $5.00.

TheStreet Quant Rating: D (Sell)